MRM vs NCL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRM presents a high-risk profile characterized by a Piotroski F-Score of 4/9 (Stable) but severe underlying liquidity distress. While the stock trades below its Graham Number ($1.27) and Intrinsic Value ($2.59), these valuation metrics are overshadowed by a catastrophic Current Ratio of 0.24 and an extreme Debt/Equity ratio of 7.86. The company is experiencing declining revenue growth (-6.70%) and deep operating losses (-25.84% margin), suggesting that the nominal net profit is likely driven by non-operating items rather than core business health.
NCL exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic 1-year price decline of 99.3%. While the company shows modest revenue growth of 14%, this is completely overshadowed by a net profit margin of -85.83% and an ROE of -201.11%. The massive discrepancy between the 52-week high ($97.28) and current price ($0.16) suggests a total collapse in investor confidence or a significant corporate event. Overall, the company is in a precarious position with negligible fundamental support.
Compare Another Pair
Related Comparisons
MRM vs NCL: Head-to-Head Comparison
This page compares MEDIROM Healthcare Technologies Inc. (MRM) and Northann Corp. (NCL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.